 SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 GLOBE NEWSWIRE -- Denali Therapeutics Inc. NASDAQ: DNLI, a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier BBB for neurodegenerative diseases, today announced biomarker proof of concept was achieved for its Transport Vehicle TV technology in a Phase 12 study of ETV:IDS DNL310 for the potential treatment of Hunter syndrome MPS II. Denalis TV platform is a proprietary technology designed to effectively deliver large therapeutic molecules such as antibodies, enzymes, proteins, and oligonucleotides across the BBB after intravenous administration. 